& Events
& Events
News
& Events
Apr 11, 2022 Inversago Pharma to present at upcoming Bloom Burton & Co. Healthcare Investor Conference to be held on May 2-3, 2022 in Toronto, ON
MONTREAL (CANADA) – April 11, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference. Details are as follows: Conference Dates: Monday, May 2 and […]
Mar 15, 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial
MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial. This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, […]
Feb 3, 2022 Inversago Pharma will participate to the 11th Annual SVB Leerink Global Healthcare Conference
Montreal, Canada – February 3, 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today that François Ravenelle, PhD, CEO, will participate to the private company days of the 11th Annual SVB Leerink Global Healthcare Conference. Conference held virtually, Feb.14-18, 2022 Private Company Days: Monday, Feb. 14 and Tuesday, Feb. 15. SVB […]
Jan 17, 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update
Company has completed the Phase 1 Clinical Trial for its INV-202 molecule Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development Metabolic disorders are a global epidemic 1 Montreal, Canada – 17 January 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the […]
